Generated by AI
Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company that develops and commercializes genetic tests to support disease risk assessment, diagnosis, treatment selection, and patient management. Its current portfolio focuses on oncology, women’s health, and pharmacogenomics, serving healthcare providers, patients, laboratories, and pharmaceutical partners. Key offerings include hereditary cancer testing through MyRisk, germline BRCA testing through BRACAnalysis CDx, and tumor profiling through MyChoice CDx, which helps identify biomarkers associated with treatment response in certain cancers. The company also provides pharmacogenomic testing designed to help clinicians evaluate how patients may respond to selected medications. Myriad’s services combine laboratory testing, genomic analysis, clinical interpretation, and reporting, connecting molecular information with medical decision-making. Headquartered in Salt Lake City, Utah, Myriad Genetics, Inc. occupies a specialized role in the healthcare market by translating genetic and molecular data into clinically actionable insights across cancer care, reproductive health, and medication management.
Website322 North 2200 West
Salt Lake City, UT, 84116
United States
The latest articles about MYGN.
Summary of Oct 20's posts. Generated by AI.
Summary of Oct 20's posts. Generated by AI.
Summary of Oct 20's posts. Generated by AI.
Summary of Oct 20's posts. Generated by AI.
Investors talking about MYGN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.